In December, the FDA granted breakthrough status for an implantable kidney replacement system for patients with end-stage ...

Burdensome health care spending in the United States is a wide-reaching issue that requires multiple solutions, according to ...

More than one-third of patients with cutaneous chronic graft-versus-host disease had a perception of treatment response that ...

Antidepressant use prior to traumatic brain injury was not associated with worse short-term outcomes for individuals ...

Political ideology is linked to Americans’ trust in scientists as sources of cancer information, study results suggest.A ...

Patients with idiopathic pulmonary fibrosis-associated chronic cough who received twice-daily oral extended release ...

The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...

Patients who participated in an intensive lifestyle medicine program before total hip and knee arthroplasty had reduced infection risk and less pain 90 days after surgery compared with those who did ...

The FDA approved a new drug application labeling supplement that allows readministration of iDose TR with a repeat treatment protocol, according to a press release from Glaukos.

Current U.S. Preventive Services Task Force screening guidelines could exclude more than 60% of patients who develop lung cancer.Conversely, an age-based approach to screening could save more than 25, ...

Abbreviated dual antiplatelet therapy after percutaneous coronary intervention using third-generation stents remained noninferior vs. 12-month DAPT for non-ST-segment elevation myocardial infarction ...

The FDA has granted breakthrough therapy designation for litifilimab in patients with cutaneous lupus erythematosus, according to a press release from manufacturer Biogen. Litifilimab (Biogen) is a ...